Literature DB >> 33135996

Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection.

Süleyman Sağır1, Ömer Bayrak1, Haluk Şen1, Seval Kul2, Sakıp Erturhan1, İlker Seçkiner1.   

Abstract

OBJECTIVE: To compare nerve growth factor (NGF) levels in patients who received antimuscarinic, versus onabotulinum toxin-A (onaBoNT-A) injection, as well as to investigate whether there is a correlation between NGF levels, and 8-item overactive bladder questionnaire(OAB-V8), urogenital distress inventory (UDI)-6, and incontinence impact questionnaire (IIQ)-7 forms.
MATERIAL AND METHODS: Fourty adult patients with OAB were enrolled in this prospective study. An antimuscarinic was prescribed to 20 naive patients, and onaBoNT-A injection was administered to 20 patients, who were refractory to antimuscarinics. Urine samples were obtained before, and after 3rd and 6th months of treatment, and NGF levels were measured. Symptom scores of OAB-V8, UDI-6,and IIQ-7 were recorded.
RESULTS: There was no significant difference between groups in terms of the initial OAB-V8, IIQ-7, and UDI-6 scores, whereas NGF values showed no significant difference over time in onaBoNT-A group (p=0.069, p=0.069). NGF levels were significantly lower in 3rd and 6th months, in patients receiving antimuscarinic (p=0.003, p=0.007); a strong correlation was found in 3rd month between the NGF levels, OAB-V8 scores (r=0.704, p=0.001), and IIQ-7 scores (r=0.676, p=0.001), and a moderate correlation between NGF levels, and UDI-6 scores (r=0.583, p=0.007). In the 6th months, a very strong correlation was found between NGF levels, and OAB-V8 scores (r=0.811, p=0.004), and a strong correlation was found between NGF levels, and IIQ-7 scores (r=0.671, p=0.001). In onaBoNT-A group, there was no significant correlation between NGF levels, and other variables.
CONCLUSION: NGF level might be a good marker to evaluate effectiveness of treatment in patients receiving antimuscarinics, owing to correlation of urinary NGF levels with symptom scores. Lack of correlation in patients receiving onaBoNT-A injection could be a result of differences in the mechanism of action.

Entities:  

Year:  2020        PMID: 33135996      PMCID: PMC8260081          DOI: 10.5152/tud.2020.20432

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  15 in total

1.  Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.

Authors:  Hsin-Tzu Liu; Heng Lin; Hann-Chorng Kuo
Journal:  Neurourol Urodyn       Date:  2011-08-08       Impact factor: 2.696

Review 2.  Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?

Authors:  Jai H Seth; Arun Sahai; Mohammad S Khan; Frank van der Aa; Dirk de Ridder; Jalesh N Panicker; Prokar Dasgupta; Clare J Fowler
Journal:  BJU Int       Date:  2013-03       Impact factor: 5.588

Review 3.  Muscarinic receptors in the bladder: from basic research to therapeutics.

Authors:  Sharath S Hegde
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders.

Authors:  William D Steers; Jeremy B Tuttle
Journal:  Nat Clin Pract Urol       Date:  2006-02

5.  Urinary neurotrophic factors in healthy individuals and patients with overactive bladder.

Authors:  Tiago Antunes-Lopes; Rui Pinto; Sérgio C Barros; Francisco Botelho; Carlos M Silva; Célia D Cruz; Francisco Cruz
Journal:  J Urol       Date:  2012-11-19       Impact factor: 7.450

Review 6.  Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019.

Authors:  Tiago Antunes-Lopes; Francisco Cruz
Journal:  Eur Urol Focus       Date:  2019-06-21

Review 7.  Biomarkers in overactive bladder.

Authors:  Alka A Bhide; Rufus Cartwright; Vik Khullar; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2013-01-12       Impact factor: 2.894

8.  Biomarkers in overactive bladder: a new objective and noninvasive tool?

Authors:  Tiago Antunes-Lopes; Sérgio Carvalho-Barros; Célia-Duarte Cruz; Francisco Cruz; Carlos Martins-Silva
Journal:  Adv Urol       Date:  2011-05-29

9.  Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients.

Authors:  Yoon Seok Suh; Kwang Jin Ko; Tae Heon Kim; Hyo Serk Lee; Hyun Hwan Sung; Won Jin Cho; Kyu-Sung Lee
Journal:  Int Neurourol J       Date:  2017-12-31       Impact factor: 2.835

Review 10.  Botulinum toxin A for the Treatment of Overactive Bladder.

Authors:  Po-Fan Hsieh; Hung-Chieh Chiu; Kuan-Chieh Chen; Chao-Hsiang Chang; Eric Chieh-Lung Chou
Journal:  Toxins (Basel)       Date:  2016-02-29       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.